Enzymatica AB (ENZY) AI Stock Analysis

• Market Cap: kr572.85M
• Dividend Yield: N/A
• Average Volume (3M): 46.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.36
• Revenue Growth: 11.87%
• EPS Growth: 26.50%
• Country: SE
• Employees: 21
• Sector: Healthcare
• Sector Strength: 47
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.08
• Shares Outstanding: 242,735,100
• 10 Day Avg. Volume: 52,894
• 30 Day Avg. Volume: 46,967
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr2.50
• Price Target Upside: 5.04% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 1

• Rating: 40 Underperform
• Price Target: kr2.50 ▲(5.04% Upside)

Enzymatica AB's overall stock score is heavily impacted by its weak financial performance, characterized by continuous losses and negative cash flow. The technical analysis shows bearish sentiment, while the valuation highlights unattractive metrics due to negative earnings. Without positive earnings call data or corporate events to offset these issues, the stock's outlook remains poor.

Enzymatica AB Business Overview & Revenue Model

Company Description

Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme mouth spray, which prevents common cold and reduces the duration of illness. It also provides enzyme formulations. The company sells mouth spray under the ViruProtect brand in Denmark; STADAProtect brand in Germany; Psysiomer Stop Virus brand in France; and Zerinol Virus Defense brand in Italy. Enzymatica AB was incorporated in 2007 and is headquartered in Lund, Sweden.

How the Company Makes Money

Enzymatica AB generates revenue primarily through the sale of its flagship product, ColdZyme, across various markets. The company employs a business model that involves the distribution of its products through pharmacies and health retailers, both directly and via strategic partnerships with local distributors. These partnerships are significant as they enable Enzymatica to expand its market reach internationally, thus contributing to its revenue growth. Additionally, the company may earn income from licensing agreements and collaborations with other firms that leverage its proprietary enzyme technology for new product development.

Enzymatica AB Financial Statement Overview

Summary

Enzymatica AB's financial health is concerning, with persistent losses and negative cash flow. Despite a strong equity base and low leverage, the inability to generate profits and positive cash flows poses significant risks. Strategic adjustments are needed to improve revenue generation and operational efficiency.

Income Statement

Enzymatica AB has faced consistent challenges in profitability, with negative net income and declining revenue. The net profit margin is negative due to substantial losses, and the gross profit margin has decreased over time. The company has not shown revenue growth, indicating struggles in market expansion or retention.

Balance Sheet

The balance sheet shows a strong equity position with a high equity ratio, signaling financial stability. However, the company has a negative return on equity due to ongoing losses. The debt-to-equity ratio is low, which is positive, but the lack of profitability remains a concern.

Cash Flow

Cash flow performance is weak, with negative operating cash flow and free cash flow. The company's reliance on financing activities to support operations raises concerns about sustainability. The cash flow coverage ratios are unfavorable, reflecting ongoing operational challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	48.43M	45.58M	50.90M	48.95M	57.24M	111.25M
Gross Profit	32.73M	30.72M	31.86M	28.45M	33.35M	75.96M
EBITDA	-49.93M	-49.23M	-41.12M	-59.97M	-38.19M	-5.23M
Net Income	-52.32M	-53.18M	-49.73M	-68.66M	-45.39M	-13.22M
Balance Sheet
Total Assets	180.96M	195.22M	125.91M	174.41M	157.04M	162.03M
Cash, Cash Equivalents and Short-Term Investments	66.62M	75.21M	8.37M	50.69M	31.62M	24.02M
Total Debt	1.88M	2.20M	18.08M	22.32M	2.60M	14.47M
Total Liabilities	23.00M	18.86M	49.30M	48.12M	32.07M	55.38M
Stockholders Equity	157.96M	176.37M	76.61M	126.29M	124.97M	106.65M
Cash Flow
Free Cash Flow	-61.99M	-60.90M	-41.02M	-68.28M	-42.00M	-15.49M
Operating Cash Flow	-61.72M	-60.51M	-40.29M	-64.57M	-35.87M	-10.65M
Investing Cash Flow	-274.00K	-393.00K	-730.00K	-3.72M	-6.13M	-4.84M
Financing Cash Flow	101.64M	127.65M	-1.39M	87.37M	49.53M	10.02M

Enzymatica AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.38
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ENZY, the sentiment is Negative. The current price of 2.38 is below the 20-day moving average (MA) of 2.52, below the 50-day MA of 2.69, and below the 200-day MA of 2.56, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 37.73 is Neutral, neither overbought nor oversold. The STOCH value of 29.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ENZY.

Enzymatica AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.81B	-0.22	-40.01%	2.29%	21.48%	-2.11%
ENZY	40 Underperform	kr572.85M	―		―	11.87%	26.50%
ORXOF	―	$73.63M	―	-344.98%	―	―	―
AC6	―	€37.27M	―	-161.07%	―	―	―
6FN	―	€10.04M	―	-191.68%	―	―	―
40M	―	€32.11M	―	-34.87%	―	―	―
ERMA	―	kr179.01M	―		―	―	―